Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal.

Fabisiak, Adam; Wlodarczyk, Jakub; Fabisiak, Natalia; Storr, Martin; Fichna, Jakub

Fabisiak, Adam; Wlodarczyk, Jakub; Fabisiak, Natalia; Storr, Martin; Fichna, Jakub.

Afiliación

Fabisiak A; Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Wlodarczyk J; Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Fabisiak N; Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Storr M; Center of Endoscopy, Starnberg, Germany.
Fichna J; Walter Brendel Center of Experimental Medicine, Ludwig Maximilians University of Munich, Munich, Germany.

J Neurogastroenterol Motil ; 23(3): 341-348, 2017 Jul 30.

Article en En | MEDLINE | ID: mdl-28551943

RESUMEN

Irritable bowel syndrome is a group of functional gastrointestinal disorders with not yet fully clarified etiology. Recent evidence suggesting that mast cells may play a central role in the pathogenesis of irritable bowel syndrome paves the way for agents targeting histamine receptors as a potential therapeutic option in clinical treatment. In this review, the role of histamine and histamine receptors is debated. Moreover, the clinical evidence of anti-histamine therapeutics in irritable bowel syndrome is discussed.

Palabras clave

Ebastine; Irritable bowel syndrome; Mast cells; Receptors, histamine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Neurogastroenterol Motil Año: 2017 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Corea del Sur

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google